These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20403547)

  • 1. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P; Dumontet C
    Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
    Sève P; Dumontet C
    Lancet Oncol; 2008 Feb; 9(2):168-75. PubMed ID: 18237851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
    Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
    Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
    Gan PP; Pasquier E; Kavallaris M
    Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome.
    Ferrandina G; Martinelli E; Zannoni GF; Distefano M; Paglia A; Ferlini C; Scambia G
    Gynecol Oncol; 2007 Feb; 104(2):326-30. PubMed ID: 17030352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
    Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
    Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.
    McCarroll JA; Gan PP; Liu M; Kavallaris M
    Cancer Res; 2010 Jun; 70(12):4995-5003. PubMed ID: 20501838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.